Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Melanoma 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Liver Neoplasms 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Cancer 1

Interventions

Ipilimumab 10Nivolumab 9Interleukin-2 5Cyclophosphamide 5pembrolizumab 3incomplete Freund's adjuvant 3fludarabine phosphate 3Radiosurgery 3Melphalan 3ADI PEG20 3sotrastaurin 2fludarabine 2Specimen Handling 2Ranibizumab 2Magnetic Resonance Spectroscopy 2MART-1 Antigen 2CTLA-4 Antigen 2Biopsy 2utomilumab 1tocilizumab 1siremadlin 1sargramostim 1ruxolitinib 1relatlimab 1pentetreotide 1obinutuzumab 1montanide ISA 51 1lifileucel 1gp100 Melanoma Antigen 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uveal Melanoma × relatlimab × Clear all
NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

TriSalus Life Sciences, Inc.

Phase 1 Terminated
67 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡